Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) and Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.
Institutional & Insider Ownership
27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Volatility & Risk
Alaunos Therapeutics has a beta of -0.87, suggesting that its share price is 187% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.
Profitability
This table compares Alaunos Therapeutics and Aclaris Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alaunos Therapeutics | N/A | -232.60% | -158.99% |
| Aclaris Therapeutics | -921.50% | -61.65% | -42.41% |
Earnings & Valuation
This table compares Alaunos Therapeutics and Aclaris Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alaunos Therapeutics | $3,000.00 | 2,232.66 | -$4.18 million | ($1.91) | -1.38 |
| Aclaris Therapeutics | $7.83 million | 58.30 | -$64.92 million | ($0.58) | -5.63 |
Alaunos Therapeutics has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings for Alaunos Therapeutics and Aclaris Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alaunos Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Aclaris Therapeutics | 1 | 0 | 5 | 3 | 3.11 |
Aclaris Therapeutics has a consensus target price of $11.33, suggesting a potential upside of 247.12%. Given Aclaris Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Aclaris Therapeutics is more favorable than Alaunos Therapeutics.
Summary
Aclaris Therapeutics beats Alaunos Therapeutics on 10 of the 15 factors compared between the two stocks.
About Alaunos Therapeutics
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
